Novel Therapy for Long QT Syndrome
Novel Therapy for Long QT Syndrome
批准号:
9152955
负责人:
David J Milan
金额:
$60.2万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-01 至 2020-03-31
关键词:
AccountingAdenosineAdrenergic beta-AntagonistsAdverse effectsAffectAgonistAnimalsArrhythmiaBindingBiological AssayBiologyCardiacCaviaCell modelCellsCessation of lifeDataDiagnosisDiseaseDrug KineticsEmotionalEventFunctional disorderGenetic studyGoalsHalf-LifeHumanImplantable DefibrillatorsIndividualInheritedLaboratoriesLeadLifeLong QT SyndromeMedicalModelingMolecular Mechanisms of ActionNatureOrganOrphanOryctolagus cuniculusParentsPatientsPermeabilityPharmaceutical PreparationsPhotoaffinity LabelsPhysiciansPhysiologyPopulationPotassiumRattusRiskSafetySeriesShockShort QT syndromeSite-Directed MutagenesisSodiumStructureStructure-Activity RelationshipSudden DeathSurrogate EndpointSyncopeSyndromeTestingTherapeuticTimeZebrafishabstractinganalogbasedesigndrug candidatehuman stem cellsimprovedin vivoinduced pluripotent stem cellnovelnovel therapeutic interventionnovel therapeuticspatch clampphase III trialprototyperesearch studysmall moleculetool
中文摘要
摘要
先天性长QT综合征(LQTS)是一种遗传性疾病,影响其他健康的人和
会增加因心律失常而猝死的风险。LQTS影响2500人中的1人,
导致美国每年4000人死亡。然而,尽管我们对
在基础生物学方面,治疗选择仍然很差。所有LQTS患者都接受β-受体阻滞剂的治疗
降低晕倒或猝死风险的努力。β-受体阻滞剂不能纠正潜在的QT间期
延长,但有助于减少心律失常的触发因素。25%的LQTS受试者将拥有
尽管服用了β-受体阻滞剂,但仍有心脏事件发生,5%的事件是猝死。对于那些幸存下来的患者
推荐使用β-受体阻滞剂、植入式除颤器(ICD)。这样的病人通常都很年轻,
ICD治疗的不良反应,包括多次更换ICD电池,虚假的ICD电击和
在他们的一生中引领着修改。纠正潜在生理学的疗法将被热切地接受
以降低持续发生心律失常的风险。
以前开发QT缩短药物的努力都没有成功,部分原因是过度缩短
QT间期。这种“过度缩短”会导致短QT综合征,其严重程度可能与
QT间期延长综合征。因此,任何治疗LQTS的候选药物都必须有限制QT缩短的方法
效果。2011年,我们的实验室发现了一类新的小分子化合物,在
长QT间期综合征斑马鱼模型。从那时起,我们将这个复合类向前移动到
以下方法:1)在斑马鱼、豚鼠、兔模型和人类干细胞模型中建立疗效
2)进行了初步的构效关系研究,使效价提高了50倍,
3)进行了初步实验,证明了自我限制行动的安全性
我们以前的LQTS治疗方法的复合类,以及4)为我们的HIT确定了一个关键目标
化合物系列在改善体内较短的循环半衰期方面,以及5)确定2MMB是一种
腺苷敏感钾电流IKATP。
我们的目标是将这类化合物进一步开发为治疗长QT综合征的药物
通过以下具体目标:1)从分子机制上研究黄曲霉毒素
2MMB的行动,2)更详细地探索苯苯胺类药物的安全性
化合物,3)进行100个新的2MMB结构类似物的结构活性研究。
我们已经组建了团队和工具来进行这些实验,这些实验将提供关键信息
关于一种新的治疗长QT综合征的方法的可行性和安全性。这个
最终交付是一种治疗这种危及生命的综合征的新疗法,这种综合症夺走了其他人的生命
健康的年轻人。
英文摘要
Abstract
Congenital long QT syndrome (LQTS) is an inherited disease that affects otherwise healthy individuals and
carries an increased risk of sudden death due to cardiac arrhythmia. LQTS affects 1 in 2500 individuals and
results in 4,000 U.S. deaths annually. However, despite significant advances in our understanding of the
fundamental biology, treatment options remain poor. All patients with LQTS are treated with beta-blockers in
an effort to reduce the risk of fainting or sudden death. Beta-blockers do not correct the underlying QT interval
prolongation, but help reduce the triggers of arrhythmias. Twenty-five percent of LQTS subjects will have
cardiac events despite beta-blockers and in 5% that event is sudden death. For those patients who survive
events on beta-blockers, implantable defibrillators (ICDs) are recommended. Such patients are often young,
compounding the adverse effects of ICD therapy, with multiple ICD battery changes, spurious ICD shocks and
lead revisions over their lifetimes. Therapies that correct the underlying physiology would be eagerly accepted
to reduce ongoing risk of arrhythmias.
Previous efforts to develop QT shortening drugs have been unsuccessful, in part due to excessive shortening
of the QT interval. Such “overshortening” causes short QT syndrome which can be as bad as or worse than
long QT syndrome. Therefore any candidate drug for LQTS must have a means of limiting the QT shortening
effect. In 2011, our laboratory discovered a novel class of small molecule compounds with beneficial activity in
a zebrafish model of long QT syndrome. Since that time we have moved this compound class forward in the
following ways: 1) Established efficacy in zebrafish, guinea pig, rabbit models, and in human stem cell models
of LQTS, 2) Conducted a preliminary structure activity relationship study, improving potency 50-fold,
3) Conducted preliminary experiments that demonstrate a safety profile of self-limited action that distinguishes
our compound class from prior therapeutic approaches to LQTS, and 4) Identified a key objective for our hit
compound series in improving in vivo short circulating half-life, and 5) Identified 2MMB as an activator of the
adenosine sensitive potassium current IKATP.
It is our goal to further develop this class of compounds into a therapeutic treatment for long QT syndrome
through the following specific aims: 1) To perform mechanistic studies of the molecular mechanism of
action of 2MMB, 2) To explore in greater detail the safety profile for the benzanilide class of
compounds, and 3) To perform structure activity studies of 100 new structural analogs of 2MMB.
We have assembled the team and the tools to conduct these experiments which will provide critical information
regarding the feasibility and safety of a novel therapeutic approach to the treatment of long QT syndrome. The
ultimate deliverable is a novel therapy for this life-threatening syndrome that claims the lives of otherwise
healthy young individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetics and Mechanisms of Mitral Valve Prolapse
-
批准号:9258482
-
项目类别:
-
资助金额:$75.88万
-
财政年份:2015
-
负责人:David J Milan
-
依托单位:
High Throughput Screening for Chemical Modifiers of Long QT Syndrome
-
批准号:8154017
-
项目类别:
-
资助金额:$62.35万
-
财政年份:2011
-
负责人:David J Milan
-
依托单位:
High Throughput Screening for Chemical Modifiers of Long QT Syndrome
-
批准号:8328584
-
项目类别:
-
资助金额:$44.19万
-
财政年份:2011
-
负责人:David J Milan
-
依托单位:
High Throughput Screening for Chemical Modifiers of Long QT Syndrome
-
批准号:8489335
-
项目类别:
-
资助金额:$39.74万
-
财政年份:2011
-
负责人:David J Milan
-
依托单位:
Electrical Silencing of the Pulmonary Veins
-
批准号:7787967
-
项目类别:
-
资助金额:$26.33万
-
财政年份:2010
-
负责人:David J Milan
-
依托单位:
Electrical Silencing of the Pulmonary Veins
-
批准号:8020040
-
项目类别:
-
资助金额:$22.02万
-
财政年份:2010
-
负责人:David J Milan
-
依托单位:
The Genetic Basis of Novel Loci Influencing Myocardial Repolarization
-
批准号:7708608
-
项目类别:
-
资助金额:$44.98万
-
财政年份:2009
-
负责人:David J Milan
-
依托单位:
A Molecular Study of Cardiac Repolarization
-
批准号:7169878
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2005
-
负责人:David J Milan
-
依托单位:
A Molecular Study of Cardiac Repolarization
-
批准号:7339296
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2005
-
负责人:David J Milan
-
依托单位:
A Molecular Study of Cardiac Repolarization in Zebrafish
-
批准号:6860634
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2005
-
负责人:David J Milan
-
依托单位:
A Molecular Study of Cardiac Repolarization in Zebrafish
-
批准号:7008583
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2005
-
负责人:David J Milan
-
依托单位:
A Molecular Study of Cardiac Repolarization
-
批准号:7569384
-
项目类别:
-
资助金额:$13.23万
-
财政年份:2005
-
负责人:David J Milan
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: